Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Neoplasm Metastasis 3 Philadelphia Chromosome 2 Ovarian Neoplasms 2 Neoplasms 2 Myeloproliferative Disorders 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia 2 Sarcoma 1 Recurrence 1 Peritoneal Neoplasms 1 Neoplasm, Residual 1 Leukemia, Myeloid 1 Hematologic Diseases 1 Genital Neoplasms, Female 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Breast Neoplasms 1 Blast Crisis 1 Appendiceal Neoplasms 1

Interventions

Doxorubicin 13 Specimen Handling 12 pembrolizumab 11 Magnetic Resonance Spectroscopy 10 Biopsy 10 Cyclophosphamide 9 X-Rays 7 Ifosfamide 7 Radiotherapy 6 Phantoms, Imaging 6 Gemcitabine 6 liposomal doxorubicin 5 Nivolumab 5 tazemetostat 4 palbociclib 4 fludarabine 4 atezolizumab 4 Temozolomide 4 Radiation 4 Nuclear Medicine Department, Hospital 4 Irinotecan 4 larotrectinib 3 cabozantinib 3 Surveys and Questionnaires 3 Ipilimumab 3 Carboplatin 3 Bevacizumab 3 ulixertinib 2 tipifarnib 2 selpercatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × nilotinib × 90 days × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡